Copyright
©The Author(s) 2022.
World J Diabetes. Oct 15, 2022; 13(10): 877-887
Published online Oct 15, 2022. doi: 10.4239/wjd.v13.i10.877
Published online Oct 15, 2022. doi: 10.4239/wjd.v13.i10.877
Figure 1 Flow chart for the study procedure.
The patients enrolled in the present study received three infusions on days 7 ± 3, 14 ± 3, and 21 ± 3. There were three visits, on days 0 ± 3, 28 ± 3, and 84 ± 3. ECG: Electrocardiogram; hUC-MSCs: Human umbilical cord blood-mesenchymal stem cells.
- Citation: Lian XF, Lu DH, Liu HL, Liu YJ, Han XQ, Yang Y, Lin Y, Zeng QX, Huang ZJ, Xie F, Huang CH, Wu HM, Long AM, Deng LP, Zhang F. Effectiveness and safety of human umbilical cord-mesenchymal stem cells for treating type 2 diabetes mellitus. World J Diabetes 2022; 13(10): 877-887
- URL: https://www.wjgnet.com/1948-9358/full/v13/i10/877.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i10.877